报价延迟最少15分钟:2026/03/21 03:23 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.34 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.00/-1.20
|
|
企业价值
463.72M
|
| 资产负债 |
|
每股账面净值
1.80
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
41.00K
|
|
每股收益
0.00
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide. |
